Insilico’s AI-designed pan-TEAD inhibitor ISM6331 produced responses in 4 of 22 pretreated mesothelioma patients; a Phase 2a is planned for 2027.
Insilico’s AI-designed pan-TEAD inhibitor ISM6331 produced responses in 4 of 22 pretreated mesothelioma patients; a Phase 2a is planned for 2027.